Trial Profile

A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imgatuzumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Biomarker

03 Nov 2016 Status changed from suspended to withdrawn prior to enrolment as per project Team decision.
17 Jan 2013 Planned initiation date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
15 Nov 2012 Planned end date changed from 1 Sep 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com